TriAltus Bioscience, LLC

TriAltus Bioscience, LLC specializes in developing biopharmaceutical products aimed at addressing unmet medical needs in oncology and autoimmune disorders through innovative therapeutics, including monoclonal antibodies. TriAltus Bioscience, LLC was founded in 2017 and is headquartered in Birmingham, US. The company focuses on the development of biopharmaceuticals and has undergone no significant operational pivots since its inception. Founded by Bob Shufflebarger, who has a history in the biotech industry, the company has raised USD 1.

60 mn in a Seed funding round in April 2019, marking it as the only recorded deal. TriAltus Bioscience specializes in the development of advanced biopharmaceutical products primarily focused on addressing unmet medical needs in oncology and autoimmune disorders. Their core product offerings include a suite of monoclonal antibodies and biologics that target specific pathways involved in disease progression. These products are designed for clinical settings, catering to hospitals, research institutions, and specialized clinics that require advanced therapeutics.

TriAltus Bioscience generates revenue through a combination of direct-to-consumer sales and partnerships with healthcare providers and research institutions. The company implements a subscription model for some of its therapeutic platforms, ensuring continuous supply and support for ongoing research and clinical applications. Business transactions involve bulk orders for its monoclonal antibody products, reflecting the value of these biopharmaceutical solutions on patient care and outcomes. In April 2019, TriAltus Bioscience, LLC raised USD 1.

575 mn in Seed funding aimed at supporting the development of new products and expanding into new markets. The company plans to launch additional biopharmaceutical products targeting oncology and autoimmune disorders by late 2024. Furthermore, TriAltus intends to expand its market presence into regions in Europe and Asia by mid-2025, capitalizing on the recent funding to scale operations and enhance product offerings.